Consolidated net sales for the fiscal year ending March 2026 exceed 610 billion yen, with a net profit of 7.36 billion yen, maintaining year-over-year levels. Segment-wise, pharmaceutical wholesale is the largest, with active progress in R&D and M&A activities.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3151","jir_company_name":"Vital K.S.K. Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/3151-20260514-03.pdf","jir_short_summary":"Consolidated net sales for the fiscal year ending March 2026 exceed 610 billion yen, with a net profit of 7.36 billion yen, maintaining year-over-year levels. Segment-wise, pharmaceutical wholesale is the largest, with active progress in R&D and M&A activities.","jir_summary":"### Performance Overview\nConsolidated net sales for the fiscal year ending March 2026 exceed 610 billion yen, with net profit reaching 7.36 billion yen, comparable to the previous year. The company has been performing steadily mainly in drug wholesale and pharmacy business, actively promoting new drugs and R&D. The largest segment is wholesale, with expanded investment through R&D expenses and M&A. The financial foundation remains solid, with the equity ratio improving to 36.6%. The dividend remains at an annual 70 yen, continuing shareholder returns.\n\n### Future Outlook and Strategy\nThe earnings forecast for the fiscal year ending March 2027 projects net sales exceeding 620 billion yen and net profit over 7.5 billion yen, with steady growth expected. The company will respond to drug price revisions and new drug launches while promoting DX and logistics efficiency. Through R&D and M&A, it aims to strengthen its business portfolio. Capital policies such as share buybacks and shareholder returns will be continued. Based on Long-Term Vision 2035, the company aims to innovate in pharmaceutical distribution and manufacturing businesses.","jir_financial_highlights":"Net Sales: 610,497\u767e\u4e07\u5186 (YoY +1.7\uff05)\nNet Income Attributable to Owners of Parent: 7,362\u767e\u4e07\u5186 (YoY +0.7\uff05)\nOperating Income: 4,027\u767e\u4e07\u5186 (YoY \u25b329.4\uff05)","jir_category":"","jir_hashtags":"#VitalKSK, #FinancialResults, #JapaneseStocks","jir_key_figures":"Net Sales: 610,497 million yen (YoY +1.7\uff05)\nNet Income Attributable to Owners of Parent: 7,362 million yen (YoY +0.7\uff05)\nEquity Ratio: 36.6% (improved from previous term)","jir_meta_title":"\u3010Vital K.S.K.\u30112026 Fiscal Year Financial Results\uff5cNet Sales Exceed 610 Billion Yen, Net Profit 7.36 Billion Yen","jir_meta_description":"Overview of Vital K.S.K. Holdings Co., Ltd.'s financial results for the fiscal year ending March 2026. Net sales exceed 610 billion yen, with a net profit of 7.36 billion yen. Includes business strategies and future outlook.","jir_og_title":"\u3010Vital K.S.K.\u30112026 Fiscal Year Financial Results\uff5cNet Sales Exceed 610 Billion Yen, Net Profit 7.36 Billion Yen","jir_og_description":"Overview of Vital K.S.K.'s 2026 financial results. Details on sales, net profit, and future strategies.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16947,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-50119","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n